Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

43.39 +1.34 (+3.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
What's Going On With Pfizer Stock?
Pfizer, Inc. (NYSE: PFE) shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Tech Stalls As Rising Bond Yields Spook Investors
It's been an inauspicious start to the 2024 trading year, with all three major indexes in the red midday. 
Via Talk Markets
Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026
Moderna Inc (NASDAQ: MRNA) is back in focus as it is making advancements in cancer treatment. 
Via Benzinga
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
This Is What Whales Are Betting On Moderna
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
Via Benzinga
Moderna Stock Is Moving Higher: What's Going On?
Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. 
Via Benzinga
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
The pair's collaboration is making waves, and there's more to come. 
Via The Motley Fool
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Winners and Losers: 2023 Stock Market Performance Review
The 2023 stock market saw steep declines followed by rapid upswings, but we're ending the year on a high note (even if some stocks aren't). 
Via InvestorPlace
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?
Some of this year's underperformers could have brighter futures. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
HBM Gets Health Boost From Drug Licensing Deals
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
Exposures COVID-19
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
Exposures COVID-19
Long-Term, Organic Revenue Growth Is A Key To Investment Success
Revenue growth is probably the easiest of the 4 check boxes to quantify. Anyone can pull up their broker's research pages, or Yahoo Finance, and look at the past 3 or 5 years of revenue. 
Via Talk Markets
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
One retail chain may have the clearest path to market-beating upside from here. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
QQQ And QQQM ETFs Top Gainers And Laggards Of 2023
This article will look at the top gainers and laggards of the two popular ETFs, which have over $17 billion and $223 billion assets, respectively. The two funds are similar, with the only difference... 
Via Talk Markets
Topics ETFs
Don’t Waste Another Minute: Dump These 3 F-Rated Stocks Now
Avoid these f-rated stocks like the plague in order to help keep your portfolio squeaky clean in the new year. 
Via InvestorPlace
Tech Stocks Set New All-Time High, Small Caps On Fire As Wall Street Bulls Run Wild: What's Driving Markets Tuesday?
Tuesday, December 19, 2023, stands now as a remarkable day in Wall Street’s history, as the technology stocks of the Nasdaq 100 mark a significant milestone, surging to new highs after a hiatus of 758... 
Via Benzinga
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
Analysts think these beaten-down stocks could rebound strongly in the new year. 
Via The Motley Fool
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results. 
Via The Motley Fool
Moderna Entering Weekly Bluebox Support Area
Moderna, Inc. is an US American pharmaceutical and biotechnology company. Founded in 2010 and headquartered in Cambridge, Massachusetts, USA, it is a part of NASDAQ100 and S&P500 indices. 
Via Talk Markets
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.